MedPath

Tavaborole

These highlights do not include all the information needed to use TAVABOROLE TOPICAL SOLUTION safely and effectively. See full prescribing information for TAVABOROLE TOPICAL SOLUTION. TAVABOROLE topical solution Initial U.S. Approval : 2014

Approved
Approval ID

22a6617b-d4b1-405e-901a-0b39a7b2837d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 15, 2023

Manufacturers
FDA

Alembic Pharmaceuticals Inc.

DUNS: 079288842

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Tavaborole

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code62332-467
Application NumberANDA212188
Product Classification
M
Marketing Category
C73584
G
Generic Name
Tavaborole
Product Specifications
Route of AdministrationTOPICAL
Effective DateDecember 15, 2023
FDA Product Classification

INGREDIENTS (4)

TAVABOROLEActive
Quantity: 43.5 mg in 1 mL
Code: K124A4EUQ3
Classification: ACTIB
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
EDETATE CALCIUM DISODIUMInactive
Code: 25IH6R4SGF
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Tavaborole - FDA Drug Approval Details